WELLNESS RESEARCH CENTER

Curriculum Vitae

Ramses Vega, M.D.

Ramses.vega.md@wellness-research-center.com

10/04/2022

Education:

Miami, FL

Bachelor of Arts in Theology studies — 1999-2001
Alpha & Omega Institute
Miami, FL

Residency in Internal Medicine and Emergency Medicine — 1989-1992
Henry Ford Hospital
Detroit, MI

Medical School — 1985-1989
San Juan Bautista Medical School
Caguas, PR

Pre-Medical and General Science Education — 1983-1998
Florida International University
Miami, FL

Pre-Medical and General Science Education — 1981-1983
St. Thomas University

Professional Experience:

Vega Medical Center — 1999-Present
Internal Medicine Practice
Miami, FL

Reliant Medical Research — 2020-Present
Principal Investigator
Miami, FL

Homestead Associates in Research — 2020-Present

Select Medical National Medical Advisory Board — 2020-Present
National Board Member Miami, FL

Curriculum Vitae

Ramses Vega, M.D.

Ramses.vega.md@wellness-research-center.com

Coral Gables Hospital Privileges Private Practice Miami, FL	2013- Present
USAT/School of Medicine Medical School Clinical Professor Monserrat, British West Indie	2013- Present
Florida International University Clinical Professor for the ARNP Program Miami, FL	2011- Present
University of Miami Hospital Privileges Voluntary Clinical Professor & Private Practice Miami, FL	2011 Present
Research Integrated Services Principal and Sub Investigator Miami, FL	2011-2014
Advanced Pharma Clinical Research Principal and Sub Investigator Miami,FL	2009-2010
Ross Medical School University Larking Hospital Internship Program Contracting Proctor Attending Physician Miami, FL	2008-2008
Kendall Regional Medical Center Privileges Private Practice Miami, FL	2007- Present
Select Specialty Hospital Chief of Staff and Private Practice Principal Investigator Miami Fl	2005- Present

RV

WELLNESS RESEARCH CENTER

Curriculum Vitae

Ramses Vega, M.D.

Ramses.vega.md@wellness-research-center.com

Harmony at Greenbrier Nursing Home
and Rehabilitation Center 2004-2008
Medical Director
Miami, FL

Hialeah Shores Nursing Home 2000-2002
Member of the Board Committee
Miami, FL

Metropolitan Hospital 1998-1999
Medical Director of House Call Program
Miami, FL

VA Hospital 1993-1994
Assistant Chief of Emergency Department
Miami, FL

Assistant Clinical Professor 1993-1994
at University of Miami
Internal Medicine Attending Physician
Miami, FL

Henry Ford Health Systems 1992-1993
Emergency and Internal Medicine Attending Physician
Dearborn and Detroit, MI

Henry Ford Health Systems 1990-1992
Emergency Department Physician
Dearborn, West Bloomfield and Detroit, MI

Assistant Clinical Professor of University of Miami Primary Care
Emergency and Internal Medicine Department
Miami, FL

Miami South Florida and Surgery Center 1984-1985
Assisting in Medical and Nursing Care Miami, FL

RV

WELLNESS RESEARCH CENTER

Curriculum Vitae

Ramses Vega, M.D.

Ramses.vega.md@wellness-research-center.com

Licenses and Certifications:

- Certification in Advanced Cardiac Life Support (ACLS)
- Florida State Medical License ME 73762
- Certification in advanced Trauma Life Support (ATLS)
- Certification in Flexible Sigmoidoscopy and Biopsy
- Michigan state, Medical License
- Federation Licensing Examination (FLEX)
- Puerto Rico State, License (pending waiver of public services)
- Puerto Rico Sate Board Part Il
- Federation Licensing examination (FLEX) Part I
- Medical Science Knowledge Profile (MSKP)

WELLNESS RESEARCH CENTER

Curriculum Vitae

Ramses Vega, M.D.

Ramses.vega.md@wellness-research-center.com

Research Experience:

- Phase I1, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of SARS- COV-2 Neutralizing Antibody BGB-DXP5931 Patients with Mild to Moderate COVID-19. Role Pl.

- Phase I11, Double Blinded, Placebo Control, Randomized Clinical Trial to Evaluate Clinical Efficacy of Favipiravir in Patients with Mild to Moderate Symptoms related to COVID-19 infection. Role Pl.

- Phase 2, Durable Response Therapy Evaluation of Early or New Onset Type I Diabetes. Role Pl.

- Phase 3, Randomized, Double Blinded, Two-way, Cross-Over, Bioequivalence Study of XXX and Taxotere in Study Participants with Locally Advanced or Metastatic Non-small Cell Lung Cancer after Platinum Therapy Failure. Role PI.

- Phase 3, Clinical Study for the Treatment of Cold Sore (LIP) Role PI.

- Phase 2, Four-Week, Multi-Center, Double-Blinded, Placebo Controlled Parallel Group Study to Evacuate the Efficacy and Safety of XXX in subjects with Type I1 diabetes mellitus with and Ascending dose safety and pharmacokinetic period. Role PI.

- Phase 2, Randomized, Double-Blinded, Placebo Controlled, Multi-center study evaluating the efficacy of doses of XXX in older patients with uncomplicated influenza, Role Pl.

- Phase 2, The efficacy and safety of XXX as adjunctive therapy for Refractory Partial Epilepsy Disorder in a Double Blinded, Randomized, Placebo-Controlled, ParallelGroup, Multicenter Clinical Trial, Role PI.

- Phase 2, Four-Week, Multi-Center, Double Blinded, Placebo Controlled Parallel Group Study to Evacuate the Efficacy and Safety of XXX in subjects with Type I1 diabetes mellitus with and Ascending dose safety and pharmacokinetic period. Role PI.

- Phase 3, Randomized, Double Blinded, Placebo Controlled, Multicenter Study of Probuphin in patients with Opioids Dependence. Role sub-I.

RV

- Phase 3, Multicenter, Randomized, Double Blinded, Placebo Controlled, Study to Evaluate Cardiovascular outcomes following treatments with a hypoglycemic agent, in addition to standard care subjects with diabetes type 11. Role Sub-I.

- Phase 3, Randomized, Double Blinded, with evaluation of the safety and efficacy of XXX in subjects with resent acute coronary syndrome. Role Sub-I.

- Phase 3, Randomized, Double blinded, Placebo controlled, Multicenter trial to assess the efficacy and safety of Oxycodone/ XXX, controlled released tablets compares to placebo in opioid experienced subjects with severe chronic pain who required around the clock opioids therapy. Role PI.

- Phase 3, Study of XXX and Acyclovir for treatment of Herpes Simplex Labialis in immunocompromised-patients. Role PI.

- Phase 3, Clinical Study designed to investigate the safety and efficacy of XXX in subjects with recurrent herpes labialis. Role PI.

- Phase 3, Double-blinded, Randomized, Compactor-Controlled study, to assess the safety, efficacy, and pharmacodynamics of 2 doses and 2 durations of XXX injection administrated intravenously in patient with complicated urinary tract infections or acute pyelonephritis. Role PI.

- Phase 2, Double-blinded, Placebo Controlled, Randomized withdrawal study to evaluate the safety and efficacy of NBI-98854 in pediatric subjects with Tourette Syndrome. Role PI.

- Phase 3, Randomized, Double blinded, Placebo-controlled study to evaluate XXX in subjects with Type Il Diabetes Mellitus who are not adequately controlled by Metformin alone. Role Pl.

- Phase 4, Multicenter, Randomized, Double blinded, Double dummy, Parallel group, active-controlled, forced-titration, 12-Week comparison of combined angiotensinneprilysin inhibition with sacubitril and valsartan

versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction (HFrEF) Evaluate-HF. Role Pl.

- Phase 3, Multicenter, Randomized, Double blinded, active-controlled study to evaluate the effects of XXX compared to Valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction. Role PI

- Phase 4, Prospective randomized 12-Week controlled study of visual field change in subjects with partial seizures receiving Pregabalin or placebo protocol XXXX. Role PI.

- Phase 2b/3, Multicenter, Randomized, Double-blinded placebo-controlled study to evaluate the safety and efficacy of XXX for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis. Role Sub-I.

- Phase 3, Multicenter, Randomized, Double blinded, active-controlled maintenance and long-tern extension study of the efficacy and safety of Upadacitinib (XXX) in subjects with Crohn's disease who completed the studies XXXX or XXXX. Role Sub-I.

- Phase 3, Multicenter, Randomized, Double blinded, placebo-controlled induction study of the efficacy and safety of Upadacitinib (XXXX) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to Biology therapy. Role Sub-I.

- Phase 3, Multicenter, Randomized, Double blinded, placebo-controlled induction study of the efficacy and safety of Upadacitinib (XXXX) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to conventional therapies but have not failed Biology therapy. Role Sub-I.

- Phase 3, Multicenter, Randomized, Double blinded, placebo-controlled study to evaluate the safety and efficacy of XXXX for induction and maintenance therapy in subjects with moderately to severely active Ulcerative Colitis. Role Sub-I.
- Phase 4, observational study to evaluate the use of a PGx test assessment in the medication regimen and disease management for patients under drugs known to be influenced by genetic variation. Role PI.

RV

- COMET-TAIL VIR-7831-5008: A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high-risk non-hospitalized patients. Role PI.

- 1487-0001: A Phase 11/111 seamless, randomized, double-blind, placebo-controlled, parallel-group, group sequential study to evaluate efficacy, safety, and tolerability of BI 767551 for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19. Role Pl.

- P3-IMU-838-RMS-01: A Multi-Center, Randomized, Double-blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiplesclerosis (ENSURE-I). Role Sub-I.

- KBP5074-3-001: A Phase3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage3b/4) chronic kidney disease. Role PI.

- INCB 50465-309: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia. Role PI.

- COVID-19 Outpatient Thrombosis Prevention Trial within ACTIV-4: A multicenter adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis. Role PI.

- A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CPIOI for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4). Role PI.

- RNLC3131: a randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid

dispersion (ssd) tablets for the delay of encephalopathy decompensation in cirrhosis (red-c). Role PI.

- A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC). Role PI.
- RNLC3132: A randomized, double-blind, placebo-controlled, multicenter Study to assess the efficacy and safety of rifaximin soluble Solid dispersion (ssd) tablets for the delay of encephalopathy Decompensation in cirrhosis (red-c). Role PI.
- A randomized, controlled, multicenter, open-label trial comparing a hospital post* discharge care pathway involving aggressive LDL-C management that includes inclisiran with usual care versus usual care alone in patients with a recent acute coronary syndrome (VICTORION-INCEPTION). Role Pl.
- A phase Ill, randomized, double-blind placebo-controlled, multicenter study to evaluate the efficacy and safety of Obinutuzumab in patients with systemic lupus erythematosus. Role Pl.
- A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CPIOI for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4). Role PI.
- A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic
  Pulmonary Fibrosis. Role PI.
- P3-nv'1U-838-RMS-01: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple sclerosis (ENSURE-I). Role Sub-I.
- Protocol No. 42847922ALZ2001: "A Multicenter, Randomized, Placebo-Controlled,Double-blind Study to Investigate the Safety, Tolerability,

and Clinical Efficacy of Seltorexant (JNJ-42847922) on Behavioral and Psychological Symptoms of Dementia in Patients with Probable Alzheimer's Disease." Role Sub-I.

-
- NMIOI A Phase 3, Double blind, Randomized, Placebo controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Alzheimer s Disease. Role Sub-I.

- Protocol No. 18-AVP-786-207. A Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP 786 (Deudextromethorphan Hydrobromide [d6 DM]/Quinidine sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia. Role Sub-I.

- SLS-002-201: a 2-part phase 2 study to assess the efficacy, safety, and tolerability of SLS002 (intranasal racemic ketamine) administered to adults with major depressive disorder at imminent risk of suicide. Role Sub-I.

- An open-label pragmatic study to assess the real-world effectiveness of Adhansia XRTM in treatment of adult and adolescent patients with ADHD in the United States. ADA4003. Role Sub-I.

- Protocol RNLC3131 SaLIX/RED-C3131: Delay of early Encephalopathy Decompensation in Advance Liver Cirrhosis. A Randomized, double-blind, Placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (SSD) immediate release tablets twice daily for the delay of encephalopathy decompensation in advance liver cirrhosis (RED-C). Participants will complete a 28-day screening period, a 72-week treatment period, and a 4-week follow-up period. Role PI

- Protocol RNLC3131 SaLIX/RED-C3132: Delay of early Encephalopathy Decompensation in Advance Liver Cirrhosis. A Randomized, double-blind, Placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (SSD) tablets for the delay of encephalopathy decompensation cirrhosis. Treatment Regiment: Rifaximin 40 mg Soluble Solid Dispersion Immediately Release Tablet (SSD-40IR) twice daily, Placebo twice Daily.

RV

- GSK122 620 GLISTEN Cholestatic Pruritus in Primary Biliary Cholangitis (PBC) A two part, Randomized, Placebo controlled, double blind, Multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).

Therapeutic Experience:

- Infections Disease: Bacterial, Parasitic and Viral Infections, HIV, Meningitis, Pneumonia, Influenza, UTI.
- Dermatology: Inflammatory and Infective Dermatitis, Acne, Fungal Disease, Eczema.
- Endocrine/Metab0lic: Diabetes Mellitus, Hyperlipidemia, Thyroids Disease, Gout.
- Cardiovascular: Coronary Artery Disease, Heart Failure, Hypertension, Venous and Arterial Disease.
- Pulmonary/ Allergy: Asthma, Allergy Rhinitis, COPD, Emphysema, Bronchial Disease.
- Musculoskeletal: Rheumatoid Arthritis, Degenerative Osteoarthritis, Osteoporosis.
- Nervous Systems: Epilepsy, Polyneuropathy, Parkinson's Disease, Pain Management.
- Mental Disorders: Major Depressive Disorder, Anxiety, ADHD, Alzheimer Disease, Ticks.
- Digestive Systems: Peptic Ulcer Disease, Inflammatory Bowel Disease, Diarrhea, Constipation.
- Hematology/Oncology: Anemia, Cancer, Bleeding Disorders, Hypercoagulable States.

RV

Ramses Vega, M.D.

Ramses.vega.md@wellness-research-center.com

Hospital Affiliations:

- Kendall Regional Medical Hospital
- Select Specialty Hospital
- Coral Gables Hospital
- Hialeah Community Hospital • Westchester General Hospital
- Larkins Community Hospital • Jackson Health System

Languages:

English – Fluent
Spanish – Fluent

RV